TKNO Alpha Teknova, Inc.
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.21
P/S
4.99
EV/EBITDA
-21.95
DCF Value
$-11.61
FCF Yield
-4.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
33.3%
Operating Margin
-39.0%
Net Margin
-41.1%
ROE
-24.3%
ROA
-17.4%
ROIC
-17.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $11.1M | $-4.6M | $— |
| Q4 null | $10.0M | $-4.8M | $— |
| FY null | $40.5M | $-17.3M | $— |
| Q3 null | $10.5M | $-4.3M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
—
Beta
0.47
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.